Test Tubes

CLINICAL TRIALS

Clinical trial research evaluates the newest medication and other treatment methods to determine if these new approaches can increase cure rates.  These new treatment trials require a team of great doctors, research analysts, and coordinators, to safely administer these new treatments and assess efficacy.  This is the final step in determining which of the thousands of new compounds and increased cancer cure rates.

CURRENT OPEN TRIALS

Protocol

WCRF 452

Protocol

WCRF 455

Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

RECENTLY COMPLETED TRIALS

Protocol

WCRF 453

Protocol

WCRF 454

Protocol

WCRF 465

Protocol WCRF 451

Protocol

GOA-NVM1

 

Protocol

GOG-0261

 

Protocol

GOG-186

 

Protocol 

GOG-0241

Protocol

GOG-0258

Protocol

08-PIR-04

Protocol 

GOA-TCOV

Protocol

3144A2-3004-WW

Protocol 

XL147-201

Protocol

GOAWP3C

Protocol

SHH4489g  -01/2011

Protocol DOXILOVC2007 -01/2011

Protocol EC-FV-04 -10/2010

Protocol MORAb-003-004 -8/2010

 

Protocol M10-747  -9/1/2010

Protocol 20060342   -2010

Protocol SPO-0010  -2010

Protocol AVF4095g  -2010

Protocol AVF4121s

Protocol AVF3206s

Protocol Perifosine 207

Protocol Perifosine 211

Protocol PXD101-CLN-8

Protocol EC-FV-02

A phase II trial evaluating the efficacy of Akynzeo in the management of chemotherapy induced nausea and vomiting in patients treated for advanced stage ovarian carcinoma

A randomized , open-label, multicenter, phase 3 study to evaluate the efficacy and safety of AVELUMAB (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer

​A randomized multicenter Phase II trial to evaluate the safety, efficacy and immunogenicity of vaccination with Folate Receptor Alpha peptides admixed with GM-CSF as a vaccine adjuvant versus GM-CSF alone in patients with Platinum Sensitive Ovarian Cancer and a response or stable disease to platinum therapy

 

 

An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma

A phase IV, randomized, double-blinded, multi-center study comparing the efficacy of Fosaprepitant with standard pre-medications to aprepitant with standard pre-medications for chemotherapy induced nausea and vomiting in patients treated for gynecological cancer

A randomized phase III trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in chemotherapy-naive patients with newly diagnosed stage I-V persistent or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus, fallopian tube, peritoneum or ovary

A randomized Phase IIB evaluation of weekly Paclitaxel (NSC #673089) plus Pazopanib (NSC #737754) (IND #75648) versus weekly Paclitaxel plus placebo in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

A GCIG intergroup multicenter phase III trial of open label Carboplatin and Paclitaxel +/- NCI-supplied agent: Bevacizumab (NSC #704865, IND #113912) compared with Oxaliplatin and Capecitabine +/- Bevacizumab as first line chemotherapy in patients with mucinous epithelial ovarian or fallopian tube cancer (MEOC)

A randomized phase III trial of Cisplatin and tumor volume directed irradiation followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for optimally debulked, advanced endometrial carcinoma

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer

A Phase I/II, Open-Label, Non-Randomized, Pilot Study of weekly Paclitaxel, every four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed with Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

A Randomized Double-Blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early HER-2/neu Overexpressed/ Amplified Breast Cancer

A Phase 2 Study of XL147 in subjects with advanced or recurrent endometrial carcinoma

A Phase II, open-label, non-randomized, multi-center study of weekly Paclitaxel and every 3 week Carboplatin for treatment of primary epithelial ovarian, fallopian tube, peritoneal or malignant peritoneal mesothelioma

A phase II multicenter, randomized, double blind, placebo controlled trial evaluating the efficacy and safety of GDC-0449 as maintenance therapy in patients with ovarian cancer in a second or third complete

A Phase II Single Arm Study of Carboplatin and DOXIL® plus Bevacizumab in Subjects with Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

A randomized phase II trial comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in combination versus PLD alone in subjects with paltinum resistant ovarian cancer

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse

A Phase 2 Randomized clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serious Ovarian Cancer

A randomized, double-blind, placebo controlled phase 2 trial of paclitaxel in combination with AMG 386 in subjects with advanced recurrent epithelial ovarian or primary peritoneal cancer

A phase 2 open-label, multicenter study of SNS‑595 injection in patients with platinum-resistant ovarian cancer

A phase II, multicenter, randomized, blinded, placebo-controlled trial of Carboplatin and Gemcitabine plus Bevacizumab in patients with platinum‑sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma

A phase II, open-label, non-randomized, pilot study of weekly paclitaxel and every four-week carboplatin with bevacizumab given every two weeks for patients newly diagnosed with stage III/IV epithelial ovarian, fallopian tube or peritoneal cancer

A Phase II, open-label, non-randomized, multi-center pilot study of Intravenous Taxol, Carboplatin, and Bevacizumab (Avastin) given every 21 days in patients with newly diagnosed stage III/IV epithelial ovarian, fallopian tube, or peritoneal cancer

A Phase IIA trial of two schedules of Perifosine in patients for whom no standard therapy exists

A randomized placebo controlled study of Perifosine in combination with single agent chemotherapy for second-line metastatic cancer patients

A phase I safety, pharmacodynamic, and pharmacokinetic study of intravenously administered PXD101 plus Carboplatin or Paclitaxel or both in patients with advanced solid tumours

A phase II study of EC 145 in patients with advanced ovarian and endometrial cancers

FORMERLY KNOWN AS THE NANCY YEARY WOMEN'S CANCER RESEARCH FOUNDATION
IN MEMORY OF NANCY AND BOB YEARY

ABOUT US >

Since 1985, the WCRF physicians have been pioneers in clinical research to improve cure rates for women with ovarian, uterine, cervical, and other gynecologic cancers.

 

WCRF designs, conducts and publishes research on new leading edge medical treatments.

WCRF is not only conducting and publishing original research but is also a clearing house for information about the latest advancements in treating gynecologic cancers for physicians and patients.

 

Subscribe to Our Newsletter

CONTACT >

T: 949-642-6165

F: 949-646-7157

E: Email

351 Hospital Road, Suite 506
Newport Beach, CA 92663

  • LinkedIn
  • Facebook
  • Twitter
  • YouTube
  • Instagram

© 2020 by Tribe of Digital Natives